LXRX
Lexicon Pharmaceuticals, Inc.1.2000
-0.0300-2.44%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A boosts T1D, HCM confidence
Q&A deepened confidence in a 2026 Zynquista T1D NDA resubmission, with STENO-1's 2,000-patient enrollment brisk and DKA rates tracking at or below inTandem's 3.5 cases per 100 patient-years for a six-month review. Sonata HCM enrollment hit 50% early, accelerating toward mid-2026 completion with strong nonobstructive uptake and no cohort caps. Pilovapitan Phase III designs now include renal expansion to GFR 30+, longer neuropathy duration, and better training, but management won't self-fund, prioritizing sotagliflozin cash burn amid active partnering. Novo explores LX9851 obesity combos via ileal brake synergy. Cash stays laser-focused on sotagliflozin. Investors watch STENO safety finalization and pilovapitan deals.
Key Stats
Market Cap
436.08MP/E (TTM)
-Basic EPS (TTM)
-0.19Dividend Yield
0%Recent Filings
10-K
FY2025 10-K: no financials
Lexicon Pharmaceuticals' 10-K for FY2025 ended December 31, 2025 lacks financial statements, revenue, profitability, or quarterly metrics, precluding analysis of annual or Q4 results. No topline figures, EPS, margins, cash flows, debt, or capex disclosed. INPEFA remains commercially available post-2023 launch, with ongoing SONATA-HCM Phase 3 trial and ZYNQUISTA type 1 diabetes NDA proceedings. No guidance provided. Clinical delays threaten momentum. Cash burn unchecked.
8-K
Q4 loss narrows sharply
Lexicon Pharmaceuticals reported Q4 2025 net loss of $15.5 million, far better than $33.8 million last year, with revenues at $5.5 million versus $26.6 million. R&D expenses plunged to $11.3 million from $26.7 million; SG&A dropped to $8.8 million from $32.3 million. Cash stood at $125.2 million end-2025, boosted by $106.7 million in February 2026 from stock sale and Novo Nordisk milestone. Pipeline advances on track: SONATA-HCM over 50% enrolled, pilavapadin Phase 3-ready.
8-K
Lexicon prices $94.6M equity raise
Lexicon Pharmaceuticals priced a $41.6M public offering of 32M common shares at $1.30, paired with $70M private placements to Invus affiliates—$29.1M for 22.4M shares, $23.9M for convertible preferred yielding up to 23.1M shares post-conversion. Deal closes February 2, 2026, but preferred converts only after 2026 stockholder vote boosts authorized commons and HSR clearance. Invus hits 51% ownership. Funds fuel R&D.
8-K
Launches stock offering
Lexicon Pharmaceuticals launched an underwritten public offering of common stock on January 29, 2026, with a concurrent private placement to Invus affiliate, its largest shareholder; underwriters get a 30-day option for more shares. Ended 2025 with $125.2M in cash, investments, and restricted cash to fund operations into 2027, bolstered by a $10M Novo Nordisk milestone. Cash lasts through key catalysts.
8-K
Corrects prospectus error
Lexicon Pharmaceuticals filed a prospectus supplement on November 6, 2025, for its $75 million at-the-market equity offering via Jefferies under a 2023 agreement. It corrected an error claiming EY audited internal controls as of December 31, 2024—a requirement from which the smaller reporting company is exempt. No audit occurred. Filing clarifies compliance.
AMLX
Amylyx Pharmaceuticals, Inc.
12.31-0.25
BLRX
BioLineRx Ltd.
3.01-0.17
CPRX
Catalyst Pharmaceuticals, Inc.
24.19+0.01
LBRX
LB Pharmaceuticals Inc
19.82-0.04
LEXX
Lexaria Bioscience Corp.
0.84-0.05
LXEO
Lexeo Therapeutics, Inc.
9.73-0.03
SCPH
scPharmaceuticals Inc.
5.67+0.00
SLXN
Silexion Therapeutics Corp
2.61+0.05
VRTX
Vertex Pharmaceuticals Incorpor
454.96-0.75
XRTX
XORTX Therapeutics Inc.
0.59-0.01